BR112022000739A2 - Anticorpos de potencialização de fator h e usos dos mesmos - Google Patents

Anticorpos de potencialização de fator h e usos dos mesmos

Info

Publication number
BR112022000739A2
BR112022000739A2 BR112022000739A BR112022000739A BR112022000739A2 BR 112022000739 A2 BR112022000739 A2 BR 112022000739A2 BR 112022000739 A BR112022000739 A BR 112022000739A BR 112022000739 A BR112022000739 A BR 112022000739A BR 112022000739 A2 BR112022000739 A2 BR 112022000739A2
Authority
BR
Brazil
Prior art keywords
antibodies
factor
fragments
potentiating
nucleic acids
Prior art date
Application number
BR112022000739A
Other languages
English (en)
Inventor
Diana Wouters
Gillian Dekkers
Ilse Jongerius
Clara Brouwer Maria
Benjamin Pouw Richard
Scott Lauder
Sridhar Govindarajan
Willem Kuijpers Taco
Taede Rispens
Tom Purcell
Original Assignee
Gemini Therapeutics Sub Inc
Stichting Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemini Therapeutics Sub Inc, Stichting Sanquin Bloedvoorziening filed Critical Gemini Therapeutics Sub Inc
Publication of BR112022000739A2 publication Critical patent/BR112022000739A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

anticorpos de potencialização de fator h e usos dos mesmos referência cruzada a pedidos relacionados. são fornecidos aqui novos anticorpos isolados, sintéticos ou recombinantes e fragmentos dos mesmos específicos para o fator h, ou ácidos nucleicos ou vetores que codificam tais anticorpos e fragmentos. é ainda fornecido neste documento o uso de tais anticorpos, fragmentos, ácidos nucleicos ou vetores para inibir a ativação do complemento e tratamento de distúrbios associados à ativação do complemento.
BR112022000739A 2019-07-17 2020-07-17 Anticorpos de potencialização de fator h e usos dos mesmos BR112022000739A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875309P 2019-07-17 2019-07-17
PCT/US2020/042627 WO2021011903A1 (en) 2019-07-17 2020-07-17 Factor h potentiating antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112022000739A2 true BR112022000739A2 (pt) 2022-04-12

Family

ID=74211270

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000739A BR112022000739A2 (pt) 2019-07-17 2020-07-17 Anticorpos de potencialização de fator h e usos dos mesmos

Country Status (13)

Country Link
US (1) US11820814B2 (pt)
EP (1) EP3999073A4 (pt)
JP (1) JP2022541275A (pt)
KR (1) KR20220057530A (pt)
CN (1) CN114828886A (pt)
AR (1) AR122286A1 (pt)
AU (1) AU2020313981A1 (pt)
BR (1) BR112022000739A2 (pt)
CA (1) CA3147638A1 (pt)
IL (1) IL289812A (pt)
MX (1) MX2022000725A (pt)
TW (1) TW202110893A (pt)
WO (1) WO2021011903A1 (pt)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
US20090004183A1 (en) 2004-07-23 2009-01-01 Taylor Ronald P Compositions and Methods for Regulating the Alternative Pathway of Complement
KR20170002684A (ko) 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
KR20150029002A (ko) 2007-06-07 2015-03-17 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
JP2013508287A (ja) 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
US9295713B2 (en) 2010-09-15 2016-03-29 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
US9926366B2 (en) 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
GB201318170D0 (en) * 2013-10-14 2013-11-27 Univ Edinburgh Proteins with Diagnostic and Therapeutic Uses
EP3066132A2 (en) 2013-11-07 2016-09-14 Novo Nordisk A/S Novel methods and antibodies for treating coagulapathy
US10357554B2 (en) 2013-11-11 2019-07-23 The United States Of America, As Represented By The Secretary Of The Army AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
CN107074939B (zh) 2014-08-20 2021-09-07 桑昆血液供给基金会 H因子增强抗体及其用途
BR112017003582B1 (pt) 2014-08-27 2024-01-09 Memorial Sloan Kettering Cancer Center Agente de anticorpo, uso do mesmo, composição farmacêutica e receptor de antígeno quimérico
WO2017114401A1 (zh) * 2015-12-31 2017-07-06 江苏匡亚生物医药科技有限公司 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用
CR20180529A (es) * 2016-04-04 2019-03-21 Bioverativ Usa Inc Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
US20190202878A1 (en) * 2016-06-28 2019-07-04 Universitat Ulm Complement inhibitors and uses thereof
US10865238B1 (en) * 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
KR20200110688A (ko) * 2018-01-15 2020-09-24 스티흐팅 산퀸 불드포르지닝 인자 h 강화 항체 및 이의 사용

Also Published As

Publication number Publication date
US20220372120A1 (en) 2022-11-24
IL289812A (en) 2022-03-01
AU2020313981A8 (en) 2024-05-30
EP3999073A4 (en) 2023-07-26
JP2022541275A (ja) 2022-09-22
AR122286A1 (es) 2022-08-31
CA3147638A1 (en) 2021-01-21
KR20220057530A (ko) 2022-05-09
AU2020313981A1 (en) 2022-03-03
EP3999073A1 (en) 2022-05-25
TW202110893A (zh) 2021-03-16
US11820814B2 (en) 2023-11-21
WO2021011903A1 (en) 2021-01-21
CN114828886A (zh) 2022-07-29
MX2022000725A (es) 2022-04-26

Similar Documents

Publication Publication Date Title
BR112019005964A2 (pt) proteínas de fusão imunomoduladoras
CL2021000519A1 (es) (divisional de solicitud 732-2018) anticuerpo anti-vegf y su uso en el tratamiento de la angiogénesis patológica.
CL2020002314A1 (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
BR112019008861A2 (pt) anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
BR112019000770A2 (pt) proteínas de ligação semelhantes a anticorpos biespecíficos que se ligam especificamente às cd3 e cd123
BR112018070600A2 (pt) receptores de células t
BR112018070625A2 (pt) receptores de células t
BR112017023646A2 (pt) proteínas agonistas de receptor de cd40 de cadeia simples
BR112022003147A2 (pt) Novos anticorpos anti-cldn18.2
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BR112019005129A2 (pt) anticorpos anti-pd-1
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
BR112018012177A2 (pt) ?moduladores de hidantação de canais kv 3?
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
BR112020009759A8 (pt) Anticorpos específicos para transcrito 3 semelhante à imunoglobulina (ilt3) e usos dos mesmos
CY1124762T1 (el) Αναστολεις πρωτεïνης δεσμευσης creb (cbp)
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
BR112021024938A2 (pt) Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
BR112022020410A2 (pt) Anticorpos anti-phf-tau e usos dos mesmos
BR112023019546A2 (pt) Anticorpos anti-tau e usos dos mesmos
BR112021010241A2 (pt) Construto multigene para expressão de proteínas imunomodulatórias e métodos de uso
MY195945A (en) Ras Protein Degradation Inducing Molecule and Pharmaceutical Composition